Drug Profile
Research programme: cancer therapeutics - Chemilia
Alternative Names: CHE-202Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Chemilia
- Class Small molecules
- Mechanism of Action Apoptosis stimulants; Tubulin polymerisation inhibitors; Vascular disrupting agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Sweden (PO)
- 19 Oct 2013 Preclinical trials in Cancer in Sweden (PO)
- 19 Oct 2013 Pharmacodynamics data from preclinical trials in Cancer presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2013)